Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2016 Jul;31(4):270-5.
doi: 10.5001/omj.2016.53.

Prevalence of Metabolic Syndrome in Patients with Schizophrenia Referred to Farabi Hospital, Kermanshah, Iran

Jalal Shakeri  1 , Kamyar Karimi  1 , Vahid Farnia  1 , Senobar Golshani  1 , Mostafa Alikhani  1
Affiliations

Prevalence of Metabolic Syndrome in Patients with Schizophrenia Referred to Farabi Hospital, Kermanshah, Iran

Jalal Shakeri et al. Oman Med J. 2016 Jul.

Abstract

Objectives: Our study was conducted to determine the prevalence of metabolic syndrome in patients with schizophrenia.

Methods: The study population included all patients with schizophrenia who were referred to Farabi Hospital, Kermanshah, Iran, between March 2014 and March 2015. A total of 280 subjects who met the study criteria were selected according to the census sampling method.

Results: The prevalence of metabolic syndrome was 30.4% (20.7% in men and 51.5% in women). The prevalence of metabolic syndrome was greater in patients > 40 years than patients aged 20-40 years. There was a significant relationship between marital status and number of hospitalizations with the prevalence of metabolic syndrome.

Conclusions: Given the high prevalence of metabolic syndrome in patients with schizophrenia, healthcare professionals should take measures to identify the risk factors and timely treatment of affected patients, thereby improving the patient's quality of life and reducing health costs.

Keywords: Metabolic Syndrome; Patients; Schizophrenia.

PubMed Disclaimer

References

    1. Sadock BJ, Sadock VA, Kaplan HI, eds. Kaplan & Sadock’s Synopsis of Psychiatry: Behavioral Sciences/Clinical Psychiatry. 10th edition. Philadelphia: Lippincott and Wilkins; 2007. p. 467-477.
    1. McGrath J, Saha S, Chant D, Welham J. Schizophrenia: a concise overview of incidence, prevalence, and mortality. Epidemiol Rev 2008;30:67-76. 10.1093/epirev/mxn001 - DOI - PubMed
    1. Sperling W, Biermann T. Mortality in patients with schizophrenia. Lancet 2009. Nov;374(9701):1592–, author reply 1592-1593.. 10.1016/S0140-6736(09)61943-7 - DOI - PubMed
    1. Tiihonen J, Lönnqvist J, Wahlbeck K, Klaukka T, Niskanen L, Tanskanen A, et al. 11-year follow-up of mortality in patients with schizophrenia: a population-based cohort study (FIN11 study). Lancet 2009. Aug;374(9690):620-627. 10.1016/S0140-6736(09)60742-X - DOI - PubMed
    1. Brown S, Kim M, Mitchell C, Inskip H. Twenty-five year mortality of a community cohort with schizophrenia. Br J Psychiatry 2010. Feb;196(2):116-121. 10.1192/bjp.bp.109.067512 - DOI - PMC - PubMed

LinkOut - more resources